In the previous post, GLP-1 agonists’ analysis revealed an extraordinary increase of 327% in spending over the years. This enormous increase makes us wonder about the trends of other anti-diabetics. In this post, we will explore the contribution of another drug class named SGLT2 Inhibitors to Medicare Part D spending.
(more…)Tag: Anti-diabetics
-
The Rise of GLP-1 Drugs in Medicare Part D (2019-2023)
The previous analysis revealed that a large portion of Medicare Part D spending was concentrated in a small number of drugs. Among all drug classes, GLP-1 agonists emerged as a clear winner. In this post, we will examine the contribution of GLP-1 drugs to Medicare Part D spending over the years (2019-2023).
(more…)